| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 27 | 2021 | 2903 | 2.310 |
Why?
|
| Asparaginase | 8 | 2021 | 196 | 1.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 26 | 2021 | 16689 | 1.000 |
Why?
|
| Salvage Therapy | 13 | 2021 | 2123 | 0.990 |
Why?
|
| Daunorubicin | 3 | 2017 | 314 | 0.730 |
Why?
|
| Etoposide | 3 | 2017 | 907 | 0.640 |
Why?
|
| Pancreatitis | 2 | 2021 | 295 | 0.640 |
Why?
|
| Antineoplastic Agents | 22 | 2021 | 14617 | 0.610 |
Why?
|
| Consolidation Chemotherapy | 3 | 2018 | 153 | 0.600 |
Why?
|
| Cytarabine | 6 | 2018 | 2014 | 0.570 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 2016 | 17 | 0.570 |
Why?
|
| Sarcoma, Myeloid | 1 | 2017 | 93 | 0.550 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2018 | 3409 | 0.540 |
Why?
|
| Castleman Disease | 1 | 2016 | 71 | 0.540 |
Why?
|
| Arabinonucleosides | 8 | 2017 | 470 | 0.530 |
Why?
|
| Rhabdoid Tumor | 2 | 2015 | 106 | 0.480 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2017 | 551 | 0.480 |
Why?
|
| Polyethylene Glycols | 3 | 2020 | 654 | 0.480 |
Why?
|
| Remission Induction | 13 | 2018 | 3656 | 0.470 |
Why?
|
| Adolescent | 40 | 2021 | 32767 | 0.460 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 82 | 0.430 |
Why?
|
| Dexamethasone | 10 | 2019 | 1516 | 0.390 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2021 | 331 | 0.380 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 2021 | 7265 | 0.370 |
Why?
|
| Vincristine | 10 | 2019 | 1583 | 0.370 |
Why?
|
| Ependymoma | 3 | 2020 | 264 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2021 | 10400 | 0.340 |
Why?
|
| Teratoma | 1 | 2011 | 248 | 0.330 |
Why?
|
| Cyclophosphamide | 10 | 2019 | 3245 | 0.320 |
Why?
|
| Peroxidase | 1 | 2009 | 133 | 0.320 |
Why?
|
| Young Adult | 26 | 2021 | 22251 | 0.320 |
Why?
|
| Pons | 3 | 2012 | 54 | 0.290 |
Why?
|
| Adenine Nucleotides | 7 | 2010 | 365 | 0.280 |
Why?
|
| Doxorubicin | 8 | 2019 | 3145 | 0.270 |
Why?
|
| Child, Preschool | 24 | 2020 | 17061 | 0.270 |
Why?
|
| Brain Stem Neoplasms | 3 | 2012 | 100 | 0.270 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 929 | 0.270 |
Why?
|
| Humans | 66 | 2021 | 270740 | 0.260 |
Why?
|
| Brain Neoplasms | 4 | 2020 | 4958 | 0.250 |
Why?
|
| Methotrexate | 5 | 2015 | 1025 | 0.250 |
Why?
|
| Male | 43 | 2021 | 128315 | 0.250 |
Why?
|
| Child | 31 | 2021 | 30559 | 0.240 |
Why?
|
| DNA | 1 | 2013 | 3050 | 0.240 |
Why?
|
| Adult | 34 | 2021 | 82040 | 0.240 |
Why?
|
| DNA Methylation | 3 | 2014 | 2765 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2021 | 5408 | 0.230 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 10708 | 0.230 |
Why?
|
| Treatment Outcome | 20 | 2017 | 33737 | 0.220 |
Why?
|
| Thioguanine | 2 | 2014 | 69 | 0.210 |
Why?
|
| Medulloblastoma | 2 | 2020 | 571 | 0.210 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2016 | 183 | 0.210 |
Why?
|
| Stem Cell Transplantation | 4 | 2017 | 1418 | 0.200 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 15218 | 0.200 |
Why?
|
| Infusions, Intraventricular | 2 | 2020 | 28 | 0.200 |
Why?
|
| Female | 40 | 2021 | 148940 | 0.190 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 95 | 0.180 |
Why?
|
| Fourth Ventricle | 2 | 2017 | 49 | 0.180 |
Why?
|
| Azacitidine | 3 | 2014 | 1218 | 0.180 |
Why?
|
| Acute Disease | 5 | 2021 | 2493 | 0.170 |
Why?
|
| Survival Analysis | 10 | 2018 | 9292 | 0.170 |
Why?
|
| Neurofibromatosis 1 | 1 | 2021 | 159 | 0.170 |
Why?
|
| Prognosis | 11 | 2021 | 22505 | 0.170 |
Why?
|
| Interferon-alpha | 2 | 2020 | 959 | 0.160 |
Why?
|
| Recurrence | 10 | 2018 | 4878 | 0.160 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 3 | 2017 | 59 | 0.160 |
Why?
|
| Thrombocythemia, Essential | 1 | 2020 | 179 | 0.160 |
Why?
|
| Piperazines | 3 | 2015 | 2145 | 0.160 |
Why?
|
| Burkitt Lymphoma | 2 | 2011 | 350 | 0.150 |
Why?
|
| Survival Rate | 6 | 2019 | 12541 | 0.150 |
Why?
|
| Polycythemia Vera | 1 | 2020 | 268 | 0.150 |
Why?
|
| Infratentorial Neoplasms | 1 | 2017 | 48 | 0.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2011 | 2635 | 0.150 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 126 | 0.140 |
Why?
|
| Exotoxins | 1 | 2017 | 76 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2017 | 7895 | 0.140 |
Why?
|
| Induction Chemotherapy | 3 | 2015 | 670 | 0.140 |
Why?
|
| Neoplasm, Residual | 4 | 2016 | 1754 | 0.140 |
Why?
|
| Adolescent Development | 1 | 2017 | 35 | 0.140 |
Why?
|
| Philadelphia Chromosome | 3 | 2018 | 852 | 0.140 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2021 | 1013 | 0.140 |
Why?
|
| Maintenance Chemotherapy | 2 | 2015 | 226 | 0.130 |
Why?
|
| Trisomy | 1 | 2017 | 240 | 0.130 |
Why?
|
| Anemia, Hemolytic | 1 | 1996 | 53 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 229 | 0.130 |
Why?
|
| Drug Monitoring | 2 | 2015 | 352 | 0.130 |
Why?
|
| Transplantation, Homologous | 2 | 2017 | 3046 | 0.120 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 477 | 0.120 |
Why?
|
| Fertility Preservation | 1 | 2017 | 151 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2017 | 261 | 0.120 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2015 | 76 | 0.120 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 965 | 0.120 |
Why?
|
| Myeloid Cells | 1 | 2016 | 273 | 0.120 |
Why?
|
| Erythrocytes | 1 | 1996 | 337 | 0.120 |
Why?
|
| Pyrimidines | 3 | 2015 | 3669 | 0.120 |
Why?
|
| Bevacizumab | 3 | 2015 | 967 | 0.120 |
Why?
|
| Middle Aged | 22 | 2021 | 90352 | 0.120 |
Why?
|
| Mercaptopurine | 1 | 2014 | 130 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2014 | 1347 | 0.120 |
Why?
|
| Translocation, Genetic | 2 | 2017 | 1286 | 0.120 |
Why?
|
| Disease-Free Survival | 6 | 2019 | 10265 | 0.110 |
Why?
|
| Receptor, EphA5 | 1 | 2013 | 8 | 0.110 |
Why?
|
| Leukocyte Count | 2 | 2013 | 735 | 0.110 |
Why?
|
| Sulfonamides | 2 | 2021 | 1933 | 0.110 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2013 | 48 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2020 | 1253 | 0.110 |
Why?
|
| Leukemia, Myeloid | 2 | 2009 | 993 | 0.110 |
Why?
|
| Osteosarcoma | 1 | 2000 | 950 | 0.100 |
Why?
|
| Neutropenia | 4 | 2009 | 1006 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2017 | 676 | 0.100 |
Why?
|
| Cytogenetic Analysis | 2 | 2004 | 574 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 1485 | 0.100 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 513 | 0.100 |
Why?
|
| Liver Failure | 1 | 2013 | 141 | 0.100 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2017 | 838 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 2313 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 4481 | 0.100 |
Why?
|
| Rituximab | 1 | 2017 | 1594 | 0.100 |
Why?
|
| Dasatinib | 1 | 2015 | 881 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2006 | 3156 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2016 | 13414 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1840 | 0.090 |
Why?
|
| Age Factors | 4 | 2014 | 5457 | 0.090 |
Why?
|
| Curcumin | 1 | 2011 | 119 | 0.090 |
Why?
|
| Sirolimus | 2 | 2014 | 831 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 196 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 831 | 0.090 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2010 | 40 | 0.090 |
Why?
|
| Hematinics | 1 | 2011 | 108 | 0.090 |
Why?
|
| Aged | 18 | 2021 | 73333 | 0.090 |
Why?
|
| Niacinamide | 1 | 2011 | 428 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 354 | 0.090 |
Why?
|
| Erythropoietin | 1 | 2011 | 224 | 0.090 |
Why?
|
| Bortezomib | 1 | 2011 | 549 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 206 | 0.080 |
Why?
|
| Imatinib Mesylate | 3 | 2015 | 1691 | 0.080 |
Why?
|
| Fever | 3 | 2009 | 521 | 0.080 |
Why?
|
| Leukemia | 2 | 2009 | 1719 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2010 | 134 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 510 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2013 | 9039 | 0.080 |
Why?
|
| Aged, 80 and over | 11 | 2018 | 30998 | 0.080 |
Why?
|
| Estradiol | 1 | 2011 | 827 | 0.080 |
Why?
|
| Benzamides | 3 | 2015 | 1879 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 600 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 2184 | 0.080 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2007 | 15 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2000 | 2665 | 0.070 |
Why?
|
| Infectious Mononucleosis | 1 | 2007 | 38 | 0.070 |
Why?
|
| Infant | 6 | 2017 | 13999 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 3844 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2007 | 185 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 3216 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2015 | 14012 | 0.060 |
Why?
|
| Anemia | 1 | 2011 | 728 | 0.060 |
Why?
|
| Gene Expression | 1 | 2013 | 3640 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2006 | 272 | 0.060 |
Why?
|
| Aminoglycosides | 2 | 2018 | 233 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 1468 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 2014 | 1437 | 0.060 |
Why?
|
| Pyridines | 1 | 2011 | 1313 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 2035 | 0.060 |
Why?
|
| Models, Biological | 2 | 2010 | 3194 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2020 | 3028 | 0.050 |
Why?
|
| Retrospective Studies | 7 | 2016 | 39890 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2009 | 3045 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 4961 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 3530 | 0.050 |
Why?
|
| Retreatment | 2 | 2015 | 448 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2004 | 322 | 0.050 |
Why?
|
| Cafe-au-Lait Spots | 1 | 2021 | 4 | 0.050 |
Why?
|
| Ciprofloxacin | 2 | 1999 | 91 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2014 | 9470 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 84 | 0.050 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2005 | 460 | 0.050 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2014 | 201 | 0.040 |
Why?
|
| Palliative Care | 1 | 2012 | 2178 | 0.040 |
Why?
|
| Neoplasms | 4 | 2010 | 15927 | 0.040 |
Why?
|
| Autoantigens | 1 | 2021 | 248 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6256 | 0.040 |
Why?
|
| Antidotes | 1 | 1999 | 27 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 1655 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1999 | 96 | 0.040 |
Why?
|
| Leucovorin | 1 | 1999 | 345 | 0.040 |
Why?
|
| Necrosis | 1 | 2000 | 595 | 0.040 |
Why?
|
| Staurosporine | 1 | 2018 | 147 | 0.040 |
Why?
|
| Extremities | 1 | 2000 | 311 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 2015 | 591 | 0.040 |
Why?
|
| Joint Diseases | 1 | 1998 | 71 | 0.040 |
Why?
|
| Pelvis | 1 | 2000 | 381 | 0.040 |
Why?
|
| Health Resources | 1 | 1999 | 171 | 0.040 |
Why?
|
| Half-Life | 2 | 2010 | 269 | 0.040 |
Why?
|
| Hospital Costs | 1 | 1999 | 244 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2016 | 1726 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2017 | 452 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 1838 | 0.030 |
Why?
|
| Bone Marrow | 2 | 2015 | 2441 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 5101 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 5056 | 0.030 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2016 | 23 | 0.030 |
Why?
|
| Antigens, CD1 | 1 | 2016 | 48 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2018 | 7044 | 0.030 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1996 | 46 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2018 | 502 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 1999 | 510 | 0.030 |
Why?
|
| Risk Factors | 3 | 2018 | 17888 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2016 | 320 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1999 | 591 | 0.030 |
Why?
|
| Fluorouracil | 1 | 1999 | 1990 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 1998 | 466 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 1958 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 492 | 0.030 |
Why?
|
| Hepatitis A | 1 | 2013 | 36 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 927 | 0.030 |
Why?
|
| Enediynes | 1 | 2012 | 13 | 0.030 |
Why?
|
| Autoantibodies | 1 | 1996 | 602 | 0.030 |
Why?
|
| Epoetin Alfa | 1 | 2011 | 27 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2015 | 718 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2010 | 1608 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2014 | 337 | 0.020 |
Why?
|
| Contrast Media | 1 | 2017 | 1499 | 0.020 |
Why?
|
| Patient Selection | 1 | 2018 | 2025 | 0.020 |
Why?
|
| Medical Records | 1 | 2012 | 442 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2015 | 677 | 0.020 |
Why?
|
| Quinazolines | 1 | 2015 | 956 | 0.020 |
Why?
|
| Biological Availability | 1 | 2010 | 225 | 0.020 |
Why?
|
| Walking | 1 | 2012 | 216 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 2 | 2006 | 1757 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2015 | 1275 | 0.020 |
Why?
|
| Apoptosis | 1 | 2004 | 7757 | 0.020 |
Why?
|
| Intestinal Perforation | 1 | 2010 | 108 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 608 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2018 | 6764 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2011 | 482 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 2345 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 481 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2828 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1335 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1563 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 529 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2011 | 581 | 0.020 |
Why?
|
| Genomics | 1 | 2018 | 2835 | 0.020 |
Why?
|
| Prednisone | 1 | 2010 | 1034 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 4328 | 0.020 |
Why?
|
| Nausea | 1 | 2009 | 539 | 0.020 |
Why?
|
| Quality of Life | 2 | 2012 | 4761 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 1269 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2000 | 5231 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 1322 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 1307 | 0.020 |
Why?
|
| Acetylation | 1 | 2006 | 515 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2016 | 4116 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 242 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 4000 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1999 | 3707 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2012 | 4019 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2003 | 123 | 0.010 |
Why?
|
| Biomarkers | 1 | 2015 | 5051 | 0.010 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 2027 | 0.010 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2006 | 617 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2004 | 622 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2004 | 690 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 2400 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15912 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 6867 | 0.010 |
Why?
|
| Episode of Care | 1 | 1999 | 9 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 1570 | 0.010 |
Why?
|
| Histones | 1 | 2006 | 1513 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2006 | 1441 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 5923 | 0.010 |
Why?
|
| Ceftazidime | 1 | 1999 | 66 | 0.010 |
Why?
|
| Cephalosporins | 1 | 1999 | 174 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8699 | 0.010 |
Why?
|
| Arthritis | 1 | 1998 | 148 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2015 | 12103 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 4130 | 0.010 |
Why?
|
| United States | 1 | 2012 | 15861 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 1999 | 907 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 6177 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 7238 | 0.010 |
Why?
|
| Texas | 1 | 1999 | 6449 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 3187 | 0.000 |
Why?
|